Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/2014
06/19/2014US20140170157 Method of selecting therapeutic indications
06/19/2014US20140170155 Method for Treating a GD2 Positive Cancer
06/19/2014US20140170147 Compositions and methods of use for antibodies of dickkopf-1
06/19/2014US20140170143 Use of an anti-cd200 antibody for prolonging the survival of allografts
06/19/2014US20140170135 Egfr expression is associated with decreased benefit from trastuzumab in the ncctg n9831 trial
06/19/2014US20140170128 Compositions for the management of glycated hemoglobin and blood glucose
06/19/2014US20140170127 Inositol pyrophosphates, and methods of use thereof
06/19/2014US20140170125 Use of cardiotrophin-1 for the treatment of kidney diseases
06/19/2014US20140170115 Enzyme and Prebiotic Combinations for Enhancing Probiotic Growth and Efficacy
06/19/2014US20140170112 Compositions for ameliorating systemic inflammation and methods for making and using them
06/19/2014US20140170111 Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
06/19/2014US20140170110 Pyridin-2(1h)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
06/19/2014US20140170107 Regulation of energy metabolism and obesity by modulating b cell activating factor (baff, blys) or baff signaling
06/19/2014US20140170081 Pharmaceutical aerosol product for administration by oral or nasal inhalation
06/19/2014US20140170079 Abuse-proofed dosage form
06/19/2014US20140170063 Dosages of Immunoconjugates of Antibodies and SN-38 for Improved Efficacy and Decreased Toxicity
06/18/2014EP2743349A1 Method for preparing nucleic acid aptamer
06/18/2014EP2743275A1 Pharmaceutical composition containing honeysuckle extract and antibiotics, pharmaceutical kit, and use of honeysuckle extract for preparation of drug
06/18/2014EP2743271A1 Pim kinase inhibitor and preparation method and use in medicinal manufacture thereof
06/18/2014EP2743270A1 Alkylamino-substituted dicyanopyridines and their amino acid ester prodrugs
06/18/2014EP2743269A1 Pim kinase inhibitor, preparation method and use thereof in drug preparation
06/18/2014EP2743268A2 Fused cyclic compounds as GPR40 receptor modulators
06/18/2014EP2743266A2 Protein kinase inhibitors (variants), use thereof in treating oncological diseases and a pharmaceutical composition based thereon
06/18/2014EP2743264A1 New crystalline form of cabazitaxel, process for the preparation and pharmaceutical compositions thereof
06/18/2014EP2743256A1 Cyclopropaneamine compound
06/18/2014EP2743255A1 Cocrystal of agomelatine with phosphoric acid
06/18/2014EP2743252A1 Tetravalent platinum complex and pharmaceutical composition containing same
06/18/2014EP2742974A1 Phenanthrene derivatives for use as medicaments
06/18/2014EP2742957A1 Polyethylene glycol derivatives of palmitoylethanolamide and analogous acylethanolamides
06/18/2014EP2742955A1 Nanoparticles based on bioconjugate of GAG
06/18/2014EP2742954A1 "Silymarin aqueous formulation"
06/18/2014EP2742946A1 Method for producing pyrostegia venusta derivatives, pyrostegia venusta derivatives, pharmaceutical compositions and uses thereof
06/18/2014EP2742945A1 Antimicrobial Locking Solutions Comprising Taurinamide Derivatives and Biologically Acceptable Salts and Acids, with the addition of Small Concentrations of Heparin
06/18/2014EP2742944A1 Immune tolerance inducer
06/18/2014EP2742943A1 Composition containing s-adenosyl-l-methionine with excellent storage stability
06/18/2014EP2742942A1 Niacinamide for inducing generation of antimicrobial peptides
06/18/2014EP2742941A1 Pharmaceutical composition containing diamine derivative
06/18/2014EP2742940A1 Salts of aza-bicyclo-di-aryl ethers for adminstration once daily, twice daily or thrice daily
06/18/2014EP2742939A1 Tetrahydropyridoethers for treatment of age-related macular degeneration (AMD)
06/18/2014EP2742938A1 Amino-acid-containing composition for enhancing recovery from muscle fatigue
06/18/2014EP2742937A1 Compositions for use in the treatment of bacterial infections
06/18/2014EP2742936A1 Fused heterocyclic compound and use thereof
06/18/2014EP2742935A1 SERF2 for the treatment of atrophy and for increasing cell growth
06/18/2014EP2742934A1 Amorphous rotigotine transdermal system
06/18/2014EP2742803A1 Isothiazolinone biocides enhanced by metal ions
06/18/2014EP2742138A2 Methods and compositions for inhibiting the growth and/or proliferation of myc-driven tumor cells
06/18/2014EP2742137A1 Novel compounds for the treatment of inflammatory bowel disease
06/18/2014EP2742136A1 Gapped oligomeric compounds comprising 5'-modified deoxyribonucleosides in the gap and uses thereof
06/18/2014EP2742135A1 Linkage modified gapped oligomeric compounds and uses thereof
06/18/2014EP2742070A1 Degradation-resistant cross-linked, low-molecular-weight hyaluronate
06/18/2014EP2742056A1 Selective antisense compounds and uses thereof
06/18/2014EP2742052A1 Chlorobis copper (i) complex compositions and methods of manufacture and use
06/18/2014EP2742051A1 Amorphous form of dolutegravir
06/18/2014EP2742050A1 Dihydrothienopyrimidines
06/18/2014EP2742049A1 Tricyclic heterocyclic compounds and jak inhibitors
06/18/2014EP2742048A1 Inhibiting transient receptor potential ion channel trpa1
06/18/2014EP2742047A1 Antibacterial piperidinyl substituted 3,4-dihydro-1h-[1,8]naphthyridinones
06/18/2014EP2742046A1 PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE
06/18/2014EP2742045A1 Antibacterial cyclopenta[c]pyrrole substituted 3,4-dihydro-1h-[1,8]naphthyridinones
06/18/2014EP2742044A1 Antibacterial homopiperidinyl substituted 3,4 dihydro 1h [1,8]naphthyridinones
06/18/2014EP2742043A1 Pyrido-pyrimidine derivatives
06/18/2014EP2742042A1 Quinazoline-2,4-dione derivatives
06/18/2014EP2742040A1 Indazole compounds, compositions and methods of use
06/18/2014EP2742039A1 Compounds for the treatment and prophylaxis of respiratory syncytial virus disease
06/18/2014EP2742036A1 N-thio-anthranilamide compounds and their use as pesticides
06/18/2014EP2742033A1 Flavonoid compounds, and methods of use thereof
06/18/2014EP2742029A1 N-(benzimimdazol-2-yl)-cyclopropane carboxamides as lysophosphatidic acid antagonists
06/18/2014EP2742027A1 N-thio-anthranilamide compounds and their use as pesticides
06/18/2014EP2742026A1 Sweet flavor modifier
06/18/2014EP2742025A1 Novel soft pde4 inhibitors
06/18/2014EP2742020A2 N1-cyclic amine-n5-substituted biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same
06/18/2014EP2742019A2 N1-cyclic amine-n5-substituted phenyl biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same
06/18/2014EP2741824A1 Use of estetrol as emergency contraceptive
06/18/2014EP2741775A1 Polymeric nanoparticles for photosensitizers
06/18/2014EP2741760A2 Tnf superfamily trimerization inhibitors
06/18/2014EP2741754A1 Use of a polysaccharide polymer from the seeds of the tamarind tree in protecting against tobacco-associated damages
06/18/2014EP2741753A2 Downregulation of mir-7 for promotion of beta cell differentiation and insulin production
06/18/2014EP2741752A2 The utility of nematode small molecules
06/18/2014EP2741751A2 Concentrated felbamate formulations for parenteral administration
06/18/2014EP2741750A1 Pharmaceutical composition comprising cefuroxime
06/18/2014EP2741749A1 Kinase inhibitor polymorphs
06/18/2014EP2741748A1 Beta-lactam compounds for enhancing t cell-mediated immune responses
06/18/2014EP2741747A1 JAK P13K/mTOR COMBINATION THERAPY
06/18/2014EP2741746A1 Chemical compounds
06/18/2014EP2741745A1 Cabazitaxel formulations and methods of preparing thereof
06/18/2014EP2741744A1 Carrier-linked prodrugs having reversible carboxylic ester linkages
06/18/2014EP2741743A1 Treatment of neurodegenerative diseases
06/18/2014EP2741742A1 Pharmaceutical composition comprising a drug containing at least one toxicophore function and n-acetyl-l-cysteine
06/18/2014EP2741741A2 Lysine demethylase inhibitors for inflammatory diseases or conditions
06/18/2014EP2741738A1 Sustained release composition of prostacyclin
06/18/2014EP2741736A1 Taste masked pharmaceutical composition
06/18/2014EP2741735A1 Funny current (if) inhibitors for use in a method of treating and preventing heart failure in feline
06/18/2014DE69331233C5 2-zykloalkyl-oder arylalkyl-derivate von nicht-säure, zyklopentane-heptanoic-säure 2-cycloalkyl or arylalkyl-derivatives of non-acid, heptanoic acid-zyklopentane
06/18/2014DE102012024434A1 Verstärkung der entschäumenden Wirkung von Polysiloxanen, zugehöriger Zusammensetzungen und Lösungen Amplification of the defoaming action of polysiloxanes, associated compositions and solutions
06/18/2014CN1899276B Composition of rheinic acid or rheinic acid compounds use in preparing medicine for preventing intestinal adhesion
06/18/2014CN1266421B Anti-cancer compounds
06/18/2014CN103874702A Novel substituted indole derivatives as gamma secretase modulators
06/18/2014CN103874701A Pyridine compounds and uses thereof
06/18/2014CN103874700A Pyrazolo[3,4-c]pyridine compounds and methods of use
06/18/2014CN103874699A Pyrazolo[4,3-c]pyridine derivatives as kinase inhibitors
1 ... 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 ... 7860